Use of calcifediol in bariatric surgery patients
AssigneeEirgen Pharma Ltd.
InventorsCharles W. Bishop, Phillip Frost
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.
Claims31
A method of treating a bariatric surgery patient having a BMI of greater than 30, comprising administering to the patient an effective amount of 25-hydroxyvitamin D wherein the 25-hydroxyvitamin D is administered in the form of a sustained release oral capsule comprising 25-hydroxyvitamin D3 and a waxy carrier in a wax matrix.
A method of treating secondary hyperparathyroidism in a bariatric surgery patient having a BMI of greater than 30, comprising administering to the patient an effective amount of 25-hydroxyvitamin D wherein the 25-hydroxyvitamin D is administered in the form of a sustained release oral capsule comprising 25-hydroxyvitamin D3 and a waxy carrier in a wax matrix, to lower the patient's plasma intact parathyroid hormone level.
A method of treating secondary hyperparathyroidism and vitamin D insufficiency or deficiency in a bariatric surgery patient having a BMI of greater than 30 and an iPTH value of at least 85 pg/mL, comprising administering to the patient an effective amount of 25-hydroxyvitamin D wherein the 25-hydroxyvitamin D is administered in the form of a sustained release oral capsule comprising 25-hydroxyvitamin D3 and a waxy carrier in a wax matrix, to lower the patient's plasma intact parathyroid hormone level by at least 30%.
Dependencies are inferred from the claim text.